{"id":756531,"date":"2023-05-09T09:53:40","date_gmt":"2023-05-09T13:53:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/"},"modified":"2023-05-09T09:53:40","modified_gmt":"2023-05-09T13:53:40","slug":"silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/","title":{"rendered":"Silo Pharma\u2019s SPC-15 Awarded U.S. Patent Protecting Ongoing R&amp;D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer\u2019s Disease"},"content":{"rendered":"<div class=\"mw_release\">\n<p>ENGLEWOOD CLIFFS, NJ, May  09, 2023  (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. \u00a0(Nasdaq: SILO) (\u201cthe Company\u201d), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 11,622,948 titled \u201cBiomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders.\u201d The new patent claims cover the use of biomarkers in determining the efficacy of the Company\u2019s portfolio drug SPC-15, a targeted prophylactic treatment utilizing ketamine compositions, as a method of treatment for a stress-induced affective disorder or stress-induced psychopathology.<\/p>\n<p align=\"justify\">\u201cThis patent is an important addition to our intellectual property, further protecting the key technology behind SPC-15 in which metabolomic biomarkers predict the response to pharmacological treatments and measure efficacy,\u201d said Eric Weisblum, Chief Executive Officer of Silo Pharma.\u00a0\u201cBased on our latest research with Columbia University on SPC-15, this IP expands the claims of the original patent.\u201d<\/p>\n<p align=\"justify\">Silo Pharma owns an option to license certain assets of which the patent forms a part currently undergoing studies at Columbia University for stress-induced affective\u00a0disorders and Alzheimer&#8217;s disease.<\/p>\n<p align=\"justify\">\n        <strong>About Silo Pharma\u00a0<\/strong>\n      <\/p>\n<p align=\"justify\">Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer\u2019s disease, and other rare neurological disorders. Silo\u2019s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B-gpSWobZAMd3bGoF_6sSsgiz5UsxCA3XnN3voIkvgJDy1prYq5_IXhbBbU1vatgu_M6ySekgNUkM_jz9_7SdpIdf4l0FMC1JFzOBMYFao4=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.silopharma.com<\/u><\/a><\/p>\n<p>\n        <strong>Forward-Looking Statements\u00a0<\/strong>\n      <\/p>\n<p>All statements other than statements of historical fact in this announcement are forward-looking statements that involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;is\/are likely to&#8221; or other similar expressions. The Company under takes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company&#8217;s filings with the SEC.<\/p>\n<p>\n        <strong>Contact\u00a0<\/strong>\n      <\/p>\n<p>800-705-0120\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=H2xCB2pEZ1S8d1NOLB-kOpzikh-6YHV6gWbiY9_l-VUgTlDFcfs8zLHMMRoymnH6hLqnaTdPJZcadytjFplhM_M00QeBTSjURE1gkuPbou4=\" rel=\"nofollow noopener\" target=\"_blank\"><u>investors@silopharma.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDcwMSM1NTgyODEwIzUwMDA2OTMzOQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YTliN2UyYWItYmRkNC00YjQwLWJiYjgtOTFhYjU3MmVkYmNjLTUwMDA2OTMzOQ==\/tiny\/Silo-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ENGLEWOOD CLIFFS, NJ, May 09, 2023 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. \u00a0(Nasdaq: SILO) (\u201cthe Company\u201d), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 11,622,948 titled \u201cBiomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders.\u201d The new patent claims cover the use of biomarkers in determining the efficacy of the Company\u2019s portfolio drug SPC-15, a targeted prophylactic treatment utilizing ketamine compositions, as a method of treatment for a stress-induced affective disorder or stress-induced psychopathology. \u201cThis patent is an important addition to our intellectual property, further protecting the key technology behind SPC-15 in which metabolomic biomarkers predict the response to pharmacological &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silo Pharma\u2019s SPC-15 Awarded U.S. Patent Protecting Ongoing R&amp;D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer\u2019s Disease&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-756531","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silo Pharma\u2019s SPC-15 Awarded U.S. Patent Protecting Ongoing R&amp;D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer\u2019s Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma\u2019s SPC-15 Awarded U.S. Patent Protecting Ongoing R&amp;D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer\u2019s Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ENGLEWOOD CLIFFS, NJ, May 09, 2023 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. \u00a0(Nasdaq: SILO) (\u201cthe Company\u201d), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 11,622,948 titled \u201cBiomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders.\u201d The new patent claims cover the use of biomarkers in determining the efficacy of the Company\u2019s portfolio drug SPC-15, a targeted prophylactic treatment utilizing ketamine compositions, as a method of treatment for a stress-induced affective disorder or stress-induced psychopathology. \u201cThis patent is an important addition to our intellectual property, further protecting the key technology behind SPC-15 in which metabolomic biomarkers predict the response to pharmacological &hellip; Continue reading &quot;Silo Pharma\u2019s SPC-15 Awarded U.S. Patent Protecting Ongoing R&amp;D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer\u2019s Disease&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-09T13:53:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDcwMSM1NTgyODEwIzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma\u2019s SPC-15 Awarded U.S. Patent Protecting Ongoing R&amp;D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer\u2019s Disease\",\"datePublished\":\"2023-05-09T13:53:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\\\/\"},\"wordCount\":457,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDcwMSM1NTgyODEwIzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\\\/\",\"name\":\"Silo Pharma\u2019s SPC-15 Awarded U.S. Patent Protecting Ongoing R&amp;D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer\u2019s Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDcwMSM1NTgyODEwIzUwMDA2OTMzOQ==\",\"datePublished\":\"2023-05-09T13:53:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDcwMSM1NTgyODEwIzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDcwMSM1NTgyODEwIzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma\u2019s SPC-15 Awarded U.S. Patent Protecting Ongoing R&amp;D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma\u2019s SPC-15 Awarded U.S. Patent Protecting Ongoing R&amp;D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer\u2019s Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma\u2019s SPC-15 Awarded U.S. Patent Protecting Ongoing R&amp;D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer\u2019s Disease - Market Newsdesk","og_description":"ENGLEWOOD CLIFFS, NJ, May 09, 2023 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. \u00a0(Nasdaq: SILO) (\u201cthe Company\u201d), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 11,622,948 titled \u201cBiomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders.\u201d The new patent claims cover the use of biomarkers in determining the efficacy of the Company\u2019s portfolio drug SPC-15, a targeted prophylactic treatment utilizing ketamine compositions, as a method of treatment for a stress-induced affective disorder or stress-induced psychopathology. \u201cThis patent is an important addition to our intellectual property, further protecting the key technology behind SPC-15 in which metabolomic biomarkers predict the response to pharmacological &hellip; Continue reading \"Silo Pharma\u2019s SPC-15 Awarded U.S. Patent Protecting Ongoing R&amp;D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer\u2019s Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-09T13:53:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDcwMSM1NTgyODEwIzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma\u2019s SPC-15 Awarded U.S. Patent Protecting Ongoing R&amp;D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer\u2019s Disease","datePublished":"2023-05-09T13:53:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/"},"wordCount":457,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDcwMSM1NTgyODEwIzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/","name":"Silo Pharma\u2019s SPC-15 Awarded U.S. Patent Protecting Ongoing R&amp;D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer\u2019s Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDcwMSM1NTgyODEwIzUwMDA2OTMzOQ==","datePublished":"2023-05-09T13:53:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDcwMSM1NTgyODEwIzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDcwMSM1NTgyODEwIzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma\u2019s SPC-15 Awarded U.S. Patent Protecting Ongoing R&amp;D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/756531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=756531"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/756531\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=756531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=756531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=756531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}